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Introduction
Generally, the prognosis for patients with stages IB and IIA cervical carcinoma who are treated with radical surgery is reasonably good. Disease recurs in ≈ 10 to 15% of patients (1) (2) (3) (4) (5) (6) . Unfortunately, however, tumor recurrence is associated with a dismal prognosis; the reported survival rate in these patients is 5 to 15% (7) (8) (9) .
A considerable number of studies have investigated risk factors for recurrence after radical surgery (10) (11) (12) (13) (14) , but only a few have dealt with the clinical aspects of recurrent carcinoma (7) (8) (9) (15) (16) (17) . Such information might help clinicians to detect recurrence in an early stage, which is one of the main reasons that patients are usually closely followed after radical surgical treatment. Although early diagnosis of recurrence is believed to be beneficial for the patient, the effectiveness of routine follow-up has recently been questioned (8) . The present study was undertaken to evaluate
Materials and Methods
From 1982 through 1991, 271 patients with cervical carcinoma stages IB and IIA, were treated in our department with radical hysterectomy and pelvic lymphadenectomy according to the Okabayashi technique (1) . The medical charts of these patients were reviewed and the following data retrieved:
1 Clinicopathological data: FIGO stage, tumor histology, tumor size (cm), depth of invasion (as a fraction of cervical penetration), lymphvascular space invasion, pelvic node metastases and parametrial involvement. 2 Follow-up data:
• site of first recurrence: pelvic vs. extrapelvic; pelvic recurrences were defined as those involving the vagina, rectum, or bladder (pelvic central) as well as those confined to the pelvic sidewall. Central recurrences extending to the pelvic sidewall were grouped as pelvic sidewall recurrences. All other recurrences were classified as extrapelvic recurrences. Patients with a combined pelvic and extrapelvic recurrence were included in the group of pelvic recurrences because the pelvic component is potentially more easily detectable by routine examination.
• symptomatology of first recurrence.
• recurrence-free interval (RFI), defined as time from primary treatment to diagnosis of first recurrence.
• detection of recurrent disease.
• treatment modalities and prognosis of recurrent disease.
Staging was done according to the rules of the International Federation of Gynecology and Obstetrics (FIGO). Postoperative radiotherapy was administered to 81 patients (30%) with adverse prognostic factors, including pelvic node metastases (N = 53), parametrial extension (N = 20), inadequate surgical excision, or spill during surgery (N = 8). Radiotherapy consisted of 40 to 50 Gy external radiation to the pelvis in 4 to 5 weeks. Patients with involved margins of the vagina and spill during surgery also received brachytherapy up to a dose of 15 Gy.
Follow-up consisted of examinations every 3 months in the first year, every 6 months in the following two years, and then annually until a follow-up duration of 10 years was reached. The routine examinations included vaginal vault cytology, physical and pelvic examination, and in patients who had received adjuvant radiotherapy, chest X-rays and ultrasound examination of the kidneys to detect asymptomatic hydronephrosis. From 1989 on, serum SCC (squamous cell carcinoma antigen) was determined at each visit. Additional radiologic or blood hematology investigations were used only if recurrence was clinically suspected. Statistical analysis was done using Student's T-test, the Chi-square test, and Fisher's exact test. Survival rates were calculated according to the method of Kaplan and Meier (18) . Results were considered significant when the P-value was less then 0.05.
Results
With a median duration of follow-up of 60 months for patients censored for death due to recurrent disease, the estimated 5-year disease-specific survival rate of the 271 patients was 92%. Recurrence occurred in 27 patients (10%). Adjuvant radiotherapy was administered to 14 of these patients (52%). Fourteen patients developed a pelvic recurrence (including three with a concomitant extrapelvic recurrence) and 13 patients, an extrapelvic recurrence. In all patients with a pelvic recurrence, histologic confirmation of recurrent carcinoma was obtained whereas this was the case in only 11 patients with extrapelvic recurrence. In one patient with combined pulmonary and paraaortic metastases and in a second patient with vertebral metastases, the diagnosis was made only on the basis of clinical symptoms and radiologic investigations. Table 1 outlines a comparison of clinicopathologic factors between patients with and without recurrence. Adenocarcinoma, pelvic node metastases, tumor size, depth of invasion, and parametrial extension were significant risk factors for recurrence by univariate analysis. The relationship between these pathological risk factors and the site of recurrence is shown in Table 2 . It was found that large tumor size and parametrial extension correlated with pelvic failure whereas nodal metastases and adjuvant radiotherapy with extrapelvic failures. Adenocarcinoma and deeply invading tumors were associated with both pelvic and extrapelvic recurrence.
The median recurrence-free interval (RFI) was 14 months (range 3-64). Seventy-seven percent of the recurrences were discovered within 3 years after primary treatment. The median RFI for patients treated by surgery alone was not significantly different from that of patients who had received adjuvant radiotherapy (15 vs. 12 months, P = 0.14). However, patients with a pelvic recurrence had a significantly shorter median RFI when compared to patients with an extrapelvic recurrence (14 vs. 17 months, P = 0.03). Thirteen of 14 pelvic recurrences (92%) were discovered within 3 years after primary treatment vs. 8 of 13 extrapelvic recurrences (62%) (P = 0.07). Table 3 demonstrates the specific sites of first recurrence related to the outcome. Among the patients with combined pelvic and extrapelvic recurrence, one had a pelvic central recurrence and two a pelvic sidewall recurrence. None of these 3 patients survived. The mortality rate of the group of patients with recurrent disease was 85% (23/27). Twenty-two patients died of recurrent carcinoma. One patient died from a large bowel perforation with accompanying sepsis following salvage pelvic radiotherapy. The mortality rate in patients with a pelvic recurrence was comparable to that of patients with an extrapelvic recurrence (86% vs. 85%). However, among the group of patients with a pelvic recurrence, only one of the 4 patients with an isolated pelvic central recurrence died of disease compared with all 7 patients with an isolated pelvic sidewall recurrence (P = 0.02). Remarkably, two patients with an isolated pulmonary recurrence survived. Both had been treated by surgical excision and have been disease-free for 4 and 8 years, respectively. Among the other 3 patients with a pulmonary recurrence who died of disease, 2 patients also had other extrapelvic recurrences. Table 4 demonstrates the mode of treatment for pelvic and extrapelvic recurrences. The 5 patients with a central recurrence (including one with a concomitant extrapelvic recurrence) were all treated with radiotherapy. One of the patients with a pelvic central recurrence developed a second large central recurrence after radiotherapy that was successfully treated with concurrent hyperthermia and chemotherapy; the latter treatment is part of an ongoing trial that investigates the curative value of concurrent hyperthermia and cisplatinum in recurrent cervical carcinoma (19) . Currently, she is without evidence of disease for more then 4 years. Among the 9 patients with a pelvic side wall recurrence, 4 were treated with radiotherapy, 4 with chemotherapy (including one with concurrent hyperthermia), and 1 patient refused treatment. The postrecurrence median survival time was 9 months (range 1-73 +). For pelvic recurrences the median survival time was 8 months compared with 9 months for extrapelvic disease. Table 5 depicts the site of recurrence related to the presence of symptoms. Symptoms were present in 65% (N = 17) of the patients with recurrent carcinoma. These symptoms included pain (N = 11), persistent cough (N = 1), vaginal discharge (N = 1), and lymphedema (N = 2). Two patients discovered the tumor by self examination. In one patient, the information regarding the symptomatology could not be retrieved. The proportion of symptomatic patients in the group of patients with a pelvic recurrence was comparable to that of the group of patients with an extrapelvic relapse (64% vs. 66%). However, among the patients with a pelvic recurrence, those with a pelvic central recurrence were more often asymptomatic when compared with those with a pelvic sidewall recurrence (4/5 vs. 1/9, P = 0.02). The death rate from recurrent carcinoma in symptomatic patients was 94% (16/17) compared with 56% (5/9) in asymptomatic patients (P = 0.04). The two patients who survived their pulmonary recurrences were asymptomatic. Table 6 shows which surveillance parameter led to the diagnosis of recurrent carcinoma. Included among the patients whose recurrence was detected by physical and pelvic examination were two patients who also had an abnormal Pap smear. The detection rate of recurrent carcinoma by routine follow-up visits was 36% (9/25). In 3 of the 5 patients with a pelvic central recurrence, the vaginal cytology was abnormal. However, in one of these patients this was the only suspicious finding.
Discussion
Tumor recurrence in surgically treated stage IB and IIA cervical carcinoma patients carries an extremely poor prognosis regardless of the kind of salvage treatment. The reported mortality rate ranges from 70% to 97% (3, 7, 8, 9, 15) . The 85% mortality rate found in this study concurs with these numbers.
Many studies have investigated prognostic factors in early cervical carcinoma patients in order to identify high-risk groups. As yet, the most significant risk factors for recurrence are adenocarcinoma, large tumor volume (tumor size, depth of invasion), and pelvic node metastases (10) (11) (12) (13) 14, 20) . This study reconfirms their prognostic significance. In an earlier report, we have demonstrated that by multivariate analysis, adenocarcinoma was the most significant factor associated with survival (21) . The present study shows that various pathological factors also affected the site of recurrence. For example, pelvic recurrences were more often seen in patients with large volume tumors (tumor size > 3 cm, depth of invasion ജ 2/3, parametrial extension). Other authors also observed a high local failure rate in bulky tumors (22, 23) . Another factor that influenced the site of recurrence in this study was the primary treatment method. In concord with the literature (2, 7, 15, 17) , we observed that patients who received adjuvant radiotherapy were more likely to develop extrapelvic recurrences compared with patients treated by surgery alone. Although patients who received adjuvant radiotherapy had more unfavorable prognostic factors such as nodal metastases, literature data suggest that this observation is the result of the beneficial effect of radiotherapy on pelvic control (24) . We observed that the majority of recurrences occurred within 3 years after primary treatment; this is in agreement with the results of other reports (7, 9, (15) (16) (17) 25, 26) . The recurrence-free interval in the present study was 14 months. This is slightly longer when compared with other studies in which this interval varies from 8 to 11 months (7, 9, (15) (16) (17) 24, 25) . This might be the result of the relatively low proportion of pelvic recurrences (52%) in our group of patients, who had a significantly shorter RFI when compared to patients with extrapelvic recurrences. The literature confirms the finding that pelvic recurrences are detected earlier than distant recurrences. Larson et al. found that 70% of the pelvic relapses were discovered within two years after treatment compared with 20% of the distant relapses (P = 0.02) (16) . Look et al. reported a significantly shorter median RFI for pelvic recurrences compared with distant recurrences (10 vs. 20 months) (15) . Literature data and the results from the present study suggest that the first three years of follow-up are critical and warrant frequent follow-up visits. Clinicians should be alert for pelvic recurrences in patients with large volume tumors whereas in patients who received adjuvant radiotherapy, extrapelvic recurrences can be expected. The latter, however, can also occur after the first 3 years.
The effectiveness of routine follow-up visits has been questioned because of its low detection rate of tumor recurrences. Ansink et al. found a detection rate at follow-up of 26% (8) . The authors reviewed the literature on this subject and found that the detection rate ranged from 16 to 37%. In our study the percentage of recurrences detected by routine check-ups in asymptomatic patients was indeed low (36%). We found, however, that these patients had a significantly better prognosis when compared with symptomatic patients. Three of the four survivors in our study were asymptomatic. Tinga et al. found similar results and reviewed the literature regarding the prognosis of asymptomatic vs. symptomatic patients (17) . The collated data showed that the cure rate among 81 symptomatic patients was 10% while it was 28% among 40 asymptomatic patients (P = 0.03). Early detection of tumor recurrence may become more important with the introduction of new, promising treatment modalities such as chemoradiation (26) and the combination of cisplatinum and hyperthermia (27) . Other arguments in favor of routine follow-up visits are the early detection of treatment complications and the psychosexual help that can be given if needed.
Another controversial issue is the value of various routine investigations such as vaginal vault cytology and chest X-rays. As to the question of routine vaginal cytology, opinions differ. Proponents stress the importance of the high specificity in central recurrences which are potentially curable (28) (29) (30) , while opponents find it a useless method because of its low sensitivity (17) . In addition, due to irradiation, false-positive cytology results can be obtained; we observed this in only 8 patients, however.
In our study, only one of the 9 asymptomatic recurrences was suspected only on the basis of routine vaginal cytology. However, this patient was cured. Based on a follow-up period of 5 years, almost 3,800 smears had to be taken to detect this one recurrence. In terms of cost-benefit, this method does not seem to be very effective.
As to the question of routine chest X-rays, Barter et al. demonstrated in a large series on pulmonary recurrences that the survival of symptomatic patients was not significantly different from that of asymptomatic patients (31) . The authors therefore do not recommend routine chest X-rays. However, we have only used this examination in 30% of the patients, namely those who had received adjuvant radiotherapy. These patients were at risk for extrapelvic recurrences ( Table 2 ). The finding in our study, that two asymptomatic patients with isolated lung metastases may be cured, raises the question whether routine chest X-rays might be beneficial in selected patients.
Serum SCC seems to correlate significantly with tumor recurrence in squamous carcinoma (32) (33) (34) . Its value as a marker for subclinical recurrence, however, remains to be determined. The number of patients in this study in whom serial SCC was determined during the follow-up period was too small to draw any meaningful conclusion.
In conclusion, this review of a group of uniformly treated cervical carcinoma patients reconfirms the very poor outcome of those patients with recurrent disease. Detection of tumor recurrence in an asymptomatic stage seems to be associated with a more favorable outcome. Unfortunately, most patients are detected in a symptomatic stage. Frequent follow-up visits during the first 3 years after treatment, and an-ticipating where recurrence can be expected might help to detect recurrence in an early asymptomatic phase. In this respect, our data suggest that there might be a role for routine chest X-rays in selected patients.
